New drug combo for advanced ENKTL lymphoma
Part of Cancer clinical trials.
This study tests a new combination of three drugs (Golidocitinib, Pegaspargase, and a PD-1 antibody) as the first treatment for people with a rare type of lymphoma called ENKTL. It aims to see if these drugs together can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of extranodal NK/T-cell lymphoma (ENKTL) and not have received any prior chemotherapy or immunotherapy for it.
- You should be 18 years or older and have a life expectancy of at least 3 months.
- You need to have at least one tumor that can be measured on a scan or seen on a PET scan (it can be in a lymph node or elsewhere).
- Your general health should be good (able to walk and take care of yourself) and your organs (liver, kidneys, heart, bone marrow) must work well enough on blood and heart tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding a new targeted drug (golidocitinib) to standard chemotherapy plus immunotherapy works better than the standard combo alone for people with advanced or non-nasal NK/T-cell lymphoma that hasn't been treated yet.
This trial tests a new drug combination for people with a rare type of lymphoma (ENKTL) that has come back or not responded after prior treatment. It aims to see if the combination can help control the disease.
This trial tests a combination of three drugs (sintilimab, pegaspargase, and GemOx) for people with a type of lymphoma called extranodal NK/T-cell lymphoma (ENKTL) that hasn't been treated before. The goal is to see if this combination helps control the disease.
This trial tests whether a new combination of chemotherapy drugs (P-GEMD) works better than the standard combination (P-Gemox) for people with certain types of natural killer/T-cell lymphoma (a rare blood cancer). It's designed for newly diagnosed or advanced-stage patients who haven't been treated yet.
This trial tests a combination of three medicines (sintilimab, chidamide, and azacitidine) to treat a rare blood cancer called extranodal NK/T-cell lymphoma (ENKTL) that hasn't been treated before. The goal is to see if this combination can control the cancer better than traditional approaches.
This trial tests a new combination of drugs (chidamide, an anti-PD-1 antibody, and pegaspargase) against a standard treatment for people with advanced-stage, newly diagnosed NK/T-cell lymphoma. It aims to see if the new combination works better and is safe.
Hear when a new NK T-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.